Modalis Therapeutics (TSE:4883) Total Operating Expense: 円741.59 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円34.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics Total Operating Expense?

Modalis Therapeutics TSE:4883 +3.03% 20 Total Operating Expense is 円741.59 Mil as of Dec. 2025. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Modalis Therapeutics's Total Operating Expense for the three months ended in Dec. 2025 was 円0.00 Mil. Modalis Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円741.59 Mil.

Modalis Therapeutics Total Operating Expense Related Terms

Modalis Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics Total Operating Expense Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 1,240.54 2,103.69 2,370.67 1,337.65 2,211.80

Modalis Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 632.88 399.07 0.00 0.00 342.52
TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modalis Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円741.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of 円741.59 Mil mean?
Modalis Therapeutics (TSE:4883) has a Total Operating Expense of 円741.59 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Modalis Therapeutics and its competitors.
Is Modalis Therapeutics' Total Operating Expense too high?
Modalis Therapeutics' current Total Operating Expense is 円741.59 Mil. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' Total Operating Expense compare to ZTS and UTHR?
Modalis Therapeutics' Total Operating Expense of 円741.59 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Modalis Therapeutics and its competitors. Modalis Therapeutics's current Total Operating Expense is 円741.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current Total Operating Expense of 円741.59 Mil. The current Total Operating Expense is 円741.59 Mil. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current Total Operating Expense is 円741.59 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円34.00
Price